We previously developed a model of opioid-induced neuroplasticity in the peripheral terminal of the nociceptor that could contribute to opioid-induced hyperalgesia, type II hyperalgesic priming. Repeated administration of mu-opioid receptor (MOR) agonists, such as DAMGO, at the peripheral terminal of the nociceptor, induces long-lasting plasticity expressed, prototypically as opioid-induced hyperalgesia and prolongation of prostaglandin E 2 -induced hyperalgesia. In this study, we evaluated the mechanisms involved in the maintenance of type II priming. Opioid receptor antagonist, naloxone, induced hyperalgesia in DAMGO-primed paws. When repeatedly injected, naloxone-induced hyperalgesia, and hyperalgesic priming, supporting the suggestion that maintenance of priming involves changes in MOR signaling. However, the knockdown of MOR with oligodeoxynucleotide antisense did not reverse priming. Mitogenactivated protein kinase and focal adhesion kinase, which are involved in the Src signaling pathway, previously implicated in type II priming, also inhibited the expression, but not maintenance of priming. However, when Src and mitogen-activated protein kinase inhibitors were coadministered, type II priming was reversed, in male rats. A second model of priming, latent sensitization, induced by complete Freund's adjuvant was also reversed, in males. In females, the inhibitor combination was only able to inhibit the expression and maintenance of DAMGO-induced priming when knockdown of G-protein-coupled estrogen receptor 30 (GPR30) in the nociceptor was performed. These findings demonstrate that the maintenance of DAMGO-induced type II priming, and latent sensitization is mediated by an interaction between, Src and MAP kinases, which in females is GPR30 dependent.
Introduction
Chronic use of opioids has been shown to produce neuroplastic changes in peripheral sensory neurons such that opioid analgesics come to induce hyperalgesia, 8, 21, 37, 46, 56 opioidinduced hyperalgesia (OIH). We recently developed a model of OIH, referred to as type II hyperalgesic priming, 9 in which repeated administration of a mu-opioid receptor (MOR) agonist, prototypically DAMGO, at the peripheral terminal of the nociceptor, induces mechanical hyperalgesia, and a long lasting increased response to prohyperalgesic mediators such as prostaglandin E 2 (PGE 2 ), in male and female rats. 9 Latent sensitization is a model similar to type II priming and, was initially found to develop in the setting of opioid-induced hyperalgesia, triggered by the repeated administration of opiates like heroin, morphine, 19, 48 fentanyl, 12, 64, 65 and remifentanil. 18 Recently, it has been suggested that administration of complete Freund's adjuvant (CFA) in the rat's hind paw also induces latent sensitization, because the CFA-induced peripheral inflammation causes an increase in the constitutive MOR activity in the spinal cord, as a consequence of the augmented release of endogenous opioids. 22, 57 Thus, in both models, DAMGOinduced type II priming 9 and CFA-induced latent sensitization 22, 57 share similar features, including production of hyperalgesia in response an opioid receptor antagonist and their long-lasting permanence. 3, 22, 57 However, the mechanism responsible for the maintenance of these primed states is unknown.
Regarding the mechanisms of maintenance of neuroplasticity, in contrast to type I priming, 27 type II is not reversed by a protein translation inhibitor. 9, 10 In fact, so far no treatment has been able to reverse this type II condition, ie, interrupt its maintenance. Thus, inhibitors of second messengers such as H-89 (a protein kinase A inhibitor 9 ), SU 6656 (a Src inhibitor 9 ), U0126 (mitogen-activated protein kinase [MAPK] inhibitor) or the focal adhesion kinase (FAK) inhibitor produced transient inhibition of priming, in male rats.
Based on studies in non-neuronal cells demonstrating that the simultaneous inhibition of Src and MAPK/extracellular signal-related kinase (ERK) can reverse plastic changes in cell function, 25, 26, 59 we investigated if the administration of inhibitors of Src and MAPK would affect the maintenance of type II hyperalgesic priming, since these 2 molecules have been shown to play a role, in series, 44, 51, 52 or parallel, 36, 75 in signaling pathways. Moreover, considering previous reports showing marked differences between the sexes in the mechanisms involved in models of chronic pain, 15, 30, 40, 41 we performed our experiments in male and female rats.
Methods

Animals
Experiments were performed on 230 to 380 g male and female Sprague-Dawley rats (Charles River Laboratories, Hollister, CA). Experimental animals were housed in a controlled environment in the animal care facility at the University of California, San Francisco, under a 12 hour light-dark cycle. Food and water were available ad libitum. The experimental protocols were approved by the Institutional Animal Care and Use Committee at UCSF and adhered to the guidelines of the American Association of Laboratory Animal Care, the National Institutes of Health (NIH), and the Committee for Research and Ethical Issues of the International Association for the Study of Pain (IASP), for the use of animals in research. During the design of experiments, all efforts were made to minimize the number of animals used and their suffering.
Nociceptive threshold testing
Mechanical nociceptive threshold was quantified using an Ugo Basile Analgesymeter® (Randall-Selitto paw-withdrawal test; Stoelting, Chicago, IL), which applies a linearly increasing mechanical force to the dorsum of the rat's hind paw, as previously described. 32, 72, 73 Rats were placed in cylindrical acrylic restrainers designed to provide adequate comfort and ventilation, allow extension of the hind leg from lateral parts in the cylinder, and minimize restraint stress. To acclimatize rats to the testing procedure, they were placed in the restrainer for 1 hour prior to starting each experiment and for 30 minutes prior to experimental manipulations. The nociceptive threshold was defined as the force, in grams, at which the rat withdrew its paw. Baseline paw-pressure nociceptive threshold was defined as the mean of the 3 readings taken before the test agents were injected. Each paw was treated as an independent measure, and each experiment was performed on a separate group of rats.
Drugs and their administration
The chemicals used in this study were PGE 2 9, 10 ), all from Sigma-Aldrich (St. Louis, MO). The stock solution of PGE 2 (1 mg/mL) was prepared in 10% ethanol and additional dilutions made with physiological solution (0.9% NaCl), yielding a final ethanol concentration ,1%. DAMGO, naloxone, and FAK inhibitor were dissolved in saline. All other drugs were dissolved in 100% DMSO (Sigma-Aldrich) and further diluted in saline containing 2% Tween 80 (Sigma-Aldrich). The final concentration of DMSO and Tween 80 was ;2%. All the intradermal administration of the drugs on the dorsum of the hind paw was performed using a 30-gauge hypodermic needle adapted to a 50 mL Hamilton syringe. SU 6656 and U0126 were diluted to a concentration of 1 mg/2 mL, and the combination of these inhibitors was injected by adding 2 mL of each of them, into the syringe, separated by a bubble of air, to avoid mixing in the same syringe. The administration of all drugs, including the combination of SU 6656 and U0126, except PGE 2 , DAMGO, or naloxone, was preceded by a hypotonic shock to facilitate cell permeability to these agents (1 mL of distilled water separated by a bubble of air to avoid mixing in the same syringe), to facilitate the entry of compounds into the nerve terminal. 14, 17 2.4. Oligodeoxynucleotide antisense to mu-opioid receptor and estrogen receptors alpha, beta and, G-protein-coupled estrogen receptor 30 mRNA
To investigate whether the mu-opioid receptor (MOR) plays a role in the maintenance of type II priming, in male rats, and whether the estrogen receptor (ER) subtype alpha (ER-a), beta (ER-b), or G-protein-coupled receptor 30 (GPR30) regulates the effect of a combination of Src and MAPK inhibitors on the expression and maintenance of type II priming in female rats, oligodeoxynucleotides (ODNs) antisense (AS) for MOR, ER-a, ER-b and, GPR30 mRNA were used. 4, 7, 24, 31, 43, 47 The AS-ODN sequence for MOR  was, 59-CGC-CCC-AGC-CTC-TTC-CTC-T-39, for ER-a, 59-CAT  GGT CAT GGT CAG-3, for ER-b, 59-GAA TGT CAT AGC TGA-39,  and for GPR30, 59-ATG TTC AGA GAG GTC CCC AG-39  (Invitrogen Life Technologies, Carlsbad, CA) , were directed against a unique region of MOR, ER-a, ER-b or, GPR30 sequence, in the rat [UniProtKB database entry P33535 (OPRM_RAT) AS sequence should block translation and downregulate the gene expression of all 8 known isoforms (MOR); GeneBank accession numbers NM_012689.1 (ER-a), NM_012754.1 (ER-b) and NM_133573 (GPR30)]. The ODN mismatch (MM) sequences, 59-CGC-CCC-GAC-CTC-TTC-CCT-T-39 for MOR, 59-ATC GTG GAT CGT GAC-39 for ER-a, 5'-AAG GTT ATC GCA AGT-3' for ER-b, and 59-AGG TCC AGA AAG ATG CCA AG-39 for GPR30 were a scrambled version of the AS sequence that has the same base pairs and GC ratio, but the order was scrambled, with little or no homology to any mRNA sequences posted at GeneBank.
Before use, ODNs were reconstituted in nuclease-free 0.9% NaCl and then administered intrathecally at a dose of 2 mg/mL in a volume of 20 mL. Type II priming was induced by repeated (hourly 3 4) intradermal injections of DAMGO (1 mg) and, 24 hours later MM or AS-ODN was injected, for 5 consecutive days, when at the sixth day (around 17 hours after the last injection of ODN), PGE 2 , (in MM or AS-ODN for MOR-treated groups) or a combination of Src and MAPK inhibitors and/or PGE 2 , (in MM or AS-ODN for ER-a, ER-b or GPR30-treated groups) were intradermally injected, and the presence of mechanical hyperalgesia evaluated. As described previously, 1 rats were anesthetized with isoflurane (2.5% in O 2 ) and ODN injected using a microsyringe with a 30-gauge needle, inserted into the subarachnoid space, between the L4 and L5 vertebrae. A total of 40 mg of ODN, in a volume of 20 mL, was then injected. The intrathecal site of injection was confirmed by a sudden flick of the rat's tail, a reflex that is evoked by subarachnoid space access and bolus injection. 58 Animals regained consciousness approximately 1 minute after completion of the injection. The use of AS-ODN to manipulate the expression of proteins, essential for their role in nociceptor sensitization, is well supported by previous studies by others, 63, [69] [70] [71] as well as our group.
7,9,10,13,31,60
Mu-opioid receptor agonist DAMGO induced changes in nociceptor function
We had shown previously that, when the selective MOR agonist DAMGO was repeatedly injected at the site of mechanical nociceptive threshold testing, it produces changes in nociceptor function such that it no longer produces anti-hyperalgesia, but now produces mechanical hyperalgesia. 2, 3, 9 The repeated injection of DAMGO also induces a latent state of hyperresponsiveness to subsequent injection of pro-algesic mediators, 9, 42 referred to as type II hyperalgesic priming. 9 This model of neuroplasticity is expressed as prolongation of the mechanical hyperalgesia induced by PGE 2 , lasting at least 4 hours, as opposed to the injection of PGE 2 in naive paws, in which hyperalgesia fully dissipated by 2 hours. 5 To investigate the changes in nociceptor function produced by previous repeated injection of DAMGO or naloxone-measured as prolonged response to a hyperalgesic mediator at a point in time when the mechanical nociceptive threshold was not different from pre-DAMGO or naloxone baseline-PGE 2 (100 ng) was injected at the same site and the hyperalgesia, evaluated after 30 minutes and again at 4 hours. The presence of hyperalgesia at the fourth hour is characteristic of priming. 6, [9] [10] [11] 28 To investigate the second messengers involved in the expression of the neuroplasticity induced by repeated exposure to MOR agonist DAMGO, inhibitors were administered 10 minutes before the injection of PGE 2 in the primed paw. If the inhibitors were able to inhibit the expression of type II priming, we evaluated their role in the maintenance of the neuroplasticity, when PGE 2 was injected again 10 to 15 days later, or at a time point when the inhibitors were no longer present (reversal protocol, 30 days). Importantly, although the activation of spinal descending systems modulates, in parallel, the response to noxious stimuli in both hind paws, our measurements were performed at the peripheral site of the nociceptor, where the phenomenon (neuroplasticity produced by repeated injections of DAMGO) is expressed. Inflammation (eg, induced by CFA) produces constitutive MOR activity that chronically suppressed nociceptive signaling in the spinal cord for months. 22, 57 Pharmacological blockade during the posthyperalgesia state with MOR inverse agonists, such as NTX, reinstated central pain sensitization, 22 ,57 a phenomenon referred to as "latent pain sensitization" 12, 18 or "latent sensitization." 49, 57 We used CFA-induced latent sensitization to evaluate if its maintenance shares the second messenger signaling pathway as MOR agonist-induced type II priming. Immediately following baseline assessment of mechanical nociceptive thresholds, male rats were anesthetized with isoflurane (2.5% in O 2 ) and injected with CFA (50 mL, non-diluted) subcutaneously into the plantar (i. pl.) surface in 1 hind paw. 57 A 25-gauge needle was inserted at an oblique angle from the heel in the middle of the hind paw. 57 Mechanical nociceptive threshold was measured by RandallSelitto paw-withdrawal test, on the dorsum of the hind paws, on days 1, 3, 5, 7, 14, 21, and 28 after the CFA injection. The mechanical nociceptive threshold decreased dramatically on day 1 and progressively returned to baseline values, at day 28. On day 28, rats were anesthetized with isoflurane (2.5% in O 2 ), and a MOR antagonist NTX or a combination of Src and MAPK inhibitors followed 5 minutes later by NTX were injected using a microsyringe with a 30-gauge needle, inserted into the subarachnoid space, between the L4 and L5 vertebrae. The combination of Src (SU 6656; 1 mg/5 mL) and MAPK (U0126; 1 mg/5 mL) inhibitors (final volume of 10 mL) or a total of 1 mg of NTX (in a volume of 20 mL or 10 mL when injected 5 minutes after the combination of Src and MAPK inhibitors), was then injected. Naltrexone was diluted in sterile saline, and the combination of Src and MAPK inhibitors was diluted in 100% DMSO (SigmaAldrich) and further diluted in saline containing 2% Tween 80 (Sigma-Aldrich). The intrathecal site of injection was confirmed by a sudden flick of the rat's tail, a reflex that is evoked by subarachnoid space access and bolus injection. 58 The mechanical nociceptive threshold was evaluated at 15, 30, 45, 60, 90 , and 120 minutes after NTX injection. 57 
Statistics
All behavioral data are presented as mean 6 SEM of N independent observations. Statistical comparisons were made using GraphPad Prism 5.0 statistical software (GraphPad Software, Inc, La Jolla, CA). A P value ,0.05 was considered statistically significant. In experiments, the dependent variable was changed in mechanical threshold paw-withdrawal, expressed as percentage change from baseline. No significant difference in the mechanical nociceptive threshold was observed before the repeated (hourly 3 4) injections of naloxone or DAMGO and immediately before injection of naloxone or inhibitors of second messengers followed 10 minutes later by PGE 2 (average mechanical nociceptive threshold before priming stimuli: 125.2 6 1.3 g for male and 122.6 6 1.0 g for female rats; average mechanical nociceptive threshold before naloxone, inhibitors or PGE 2 injection: 124.8 6 1.2 g for male and 122.8 6 1.1 g for female rats; N 5 90 paws (males) and 120 paws (females); paired Student's t test, t 89 5 0.0874, P 5 0.9307 [males] and t 119 5 0.1838, P 5 0.8549 [females]). Of note, where ODN treatments were performed, we used 6 rats (12 paws) for each group; the left and right hind paws were used and considered as independent subjects. 29 Also, 12 male rats received an intraplantar injection of CFA in 1 hind paw, but both paws were evaluated. 57 The total number of rats used in this study was 96 males and 66 females. As specified in the figure legends, one-or two-way repeated-measures analysis of variance (ANOVA), followed by Bonferroni post hoc test, was performed to compare the mechanical hyperalgesia induced by naloxone, NTX, PGE 2 or the prolongation of the PGE 2 -induced hyperalgesia, with the control (vehicle)-and inhibitor-treated groups, at the indicated time points.
Results
The mu-opioid receptor inverse agonist naloxone induces hyperalgesia in DAMGO-primed paws in male rats
We have shown that the repeated (hourly 3 4) intradermal injections of an MOR agonist DAMGO induced hyperalgesia, after the fourth injection and, prolongation of PGE 2 -induced hyperalgesia. 9 To test if this neuroplasticity is dependent on the MOR, we tested if naloxone would produce hyperalgesia in male rats primed 1 week before, with repeated exposure to DAMGO. A single intradermal injection of naloxone (1 mg) induced a robust decrease in the mechanical nociceptive threshold, observed at 30 minutes and 1 hour after injection, in DAMGO-primed (Fig. 1A , black bars) but not in vehicle-treated paws (Fig. 1A , dotted bars), indicating that naloxone, can reinstate the hyperalgesia in DAMGO-primed paws.
Repeated exposure to naloxone induces hyperalgesia and hyperalgesic priming
The induction of hyperalgesia by naloxone, which does not induce hyperalgesia in naive paws, 3 in DAMGO-primed paws suggested that DAMGO (hourly 3 4) might have induced changes in MOR signaling.
To determine if naloxone, which also acts as an inverse agonist on MOR, can also induce type II priming, we tested if its repeated injection also induces hyperalgesia and/or prolongation of PGE 2 -induced hyperalgesia. Male rats received repeated (hourly 3 4) intradermal injections of naloxone. Thirty minutes after the fourth injection, a robust decrease in the mechanical nociceptive threshold (Fig. 1B , gray bar) was observed, similar to the effect of MOR agonist DAMGO. 9 One week after the repeated exposure to vehicle (black bars) or naloxone (gray bars), PGE 2 was injected at the same site. Mechanical hyperalgesia was observed in both groups 30 minutes after the injection of PGE 2 (Fig. 1B) . The prolongation of PGE 2 -induced hyperalgesia was, however, observed only in the group previously treated with repeated injections of naloxone (Fig. 1B, gray bar) . This data supports the idea that changes in MOR contribute to type II hyperalgesic priming.
Knockdown of mu-opioid receptor does not reverse DAMGO-induced type II priming in male rats
To determine if the presence of type II priming is due to changes in the MOR, affecting its downstream signaling pathway, we evaluated whether the knockdown of the MOR in primed nociceptors would affect the expression of type II priming induced by repeated (hourly 3 4) injections of DAMGO. Type II priming was induced in male rats and, 24 hours later, intrathecal treatment with MM-or AS-ODN for MOR mRNA was administered daily for 5 consecutive days. On the sixth day, ;17 hours after the last ODN injection, PGE 2 was injected in the dorsum of the hind paw. Treatment with AS-ODN for MOR did not affect the prolongation of PGE 2 -induced hyperalgesia, indicating that MOR does not play a role in the expression of type II priming (Fig. 2) . In addition, when we injected a single dose of DAMGO, 8 days after the last injection of MM-ODN or AS-ODN, it produced hyperalgesia in both groups, indicating that MOR did not participate in the maintenance of type II priming. The treatment with AS-ODN for MOR also did not affect the magnitude of PGE 2 hyperalgesia. 43 
Second messengers involved in the expression and maintenance of type II priming in male rats
In our previous study of DAMGO-induced priming, inhibitors of PKA (H-89) and Src (SU 6656) 9 inhibited the expression of priming in male rats. However, these inhibitors did not affect the maintenance of type II priming. 9 Here, we evaluated the participation of MAPK and FAK, 2 kinases involved in the signaling pathways in which PKA and Src participate. 20, 35, 50, 53 We found that treatment with MAPK inhibitor U0126, 10 minutes before PGE 2 , inhibited the expression of type II priming (Fig. 3A) . However, when PGE 2 was injected again, 10 days after the MAPK inhibitor, the prolongation of PGE 2 -induced hyperalgesia was present, indicating that priming has not been reversed (Fig. 3B) . When we evaluated the participation of FAK in the expression of type II priming, we found that treatment with a FAK inhibitor only partially attenuated the hyperalgesia induced by PGE 2 at 30 minutes and 4 hours after its injection (Fig. 3C) , showing a small role of FAK in the expression of type II priming.
Combination of a Src and MAPK inhibitors reverses type II priming and latent sensitization in male rats
We have previously shown that the Src inhibitor, SU 6656, blocked the expression, but not the maintenance, of type II priming in male rats. 9 Here, we found that the MAPK inhibitor also Figure 1 . Naloxone induces hyperalgesia in DAMGO-primed paws and after repeated exposure to naloxone, in male rats. (A) Male rats received repeated (hourly 34) intradermal injection of vehicle (5 mL) or DAMGO (1 mg) on the dorsum of the hind paw. One week later (1 w), naloxone (1 mg) was injected at the same site and, the mechanical nociceptive threshold, evaluated. In the group primed by repeated injections of DAMGO, naloxone induced robust mechanical hyperalgesia (black bars), observed 30 minutes and 1 hour after its injection (F 1,30 ; ***P , 0.0001, when DAMGO-primed and the vehicle groups that received naloxone are compared; two-way repeated-measures analysis of variance (ANOVA) followed by Bonferroni post hoc test), indicating that naloxone, an MOR inverse agonist, can reinstate the hyperalgesia in DAMGO-primed paws (N 5 6 paws per group). (B) A different group of male rats received repeated (hourly 3 4) intradermal injections of vehicle (5 mL) or naloxone (1 mg) on the dorsum of the hind paw. Thirty minutes after the fourth injection of vehicle or naloxone, the mechanical nociceptive thresholds were evaluated, and significant mechanical hyperalgesia was observed in the naloxone-treated group (F 1,10 5 111.76; ***P , 0.0001, when the naloxone-and vehicletreated groups are compared; two-way repeated-measures ANOVA followed by Bonferroni post hoc test). One week later, when prostaglandin E 2 (100 ng) was injected, at the same site as naloxone or vehicle, mechanical hyperalgesia was observed 30 minutes after its injection in both groups. In the group that received repeated injections of naloxone, prostaglandin E 2 -induced hyperalgesia was still present at the fourth hour after injection (F 1,20 5 75.18; ***P , 0.0001, when naloxone-and vehicle-treated groups are compared; two-way repeated-measures ANOVA followed by Bonferroni post hoc test), suggesting that changes in MOR signaling maintain the nociceptor plasticity (N 5 6 paws per group).
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inhibited the expression, but did not reverse, type II priming (Fig.  3A) . We next combined these second messenger inhibitors, which had effects on the expression of type II priming, to test its effect on the neuroplasticity produced by repeated exposure to MOR agonist DAMGO. 9 In male rats, pretreatment with the combination of Src and MAPK inhibitors attenuated the PGE 2 -induced hyperalgesia, measured 30 minutes after injection, and completely blocked the prolongation of PGE 2 -induced hyperalgesia in DAMGOprimed paws (Fig. 4A) and also, in naloxone-primed paws (data not shown). This effect was still present when the tests with PGE 2 were performed again after 15 (Figs. 4B) and 30 days (Fig. 4C) indicating that, when both Src and MAPK are inhibited, DAMGO or naloxone-induced priming can be reversed in male rats.
It has been demonstrated that CFA, injected in the paw, induces a latent sensitization 22, 57 and, a pharmacological blockade during the posthyperalgesia state with MOR inverse agonists, such as naloxone or NTX, reinstated pain. 22, 57 We injected CFA (50 mL) into the plantar surface of 1 hind paw (ipsilateral paw), and the mechanical nociceptive threshold was evaluated, in both paws, until the nociceptive threshold had returned to baseline values, 28 days after injection (Fig. 5A, black circles) . On day 28, male rats received an intrathecal injection of the MOR antagonist NTX, or a combination of Src and MAPK inhibitors, followed 5 minutes later by NTX (Fig. 5B, C) . Intrathecal NTX induced a robust decrease in mechanical nociceptive threshold, in both the ipsi and contralateral paws (Fig. 5B, C , white and black circles). However, when the combination of Src and MAPK inhibitors was injected 5 minutes before NTX, the decrease in mechanical nociceptive threshold induced by NTX was blocked, in both paws (Fig. 5B, C , white and black square). These data support the suggestion that the constitutive MOR activity induced by intraplantar CFA is dependent on Src and MAP kinase second messengers as was found for type II priming.
Combination of Src and MAPK inhibitors does not reverse type II priming in females
Our previous study demonstrated that repeated exposure to DAMGO also induced type II priming in female rats. 9 However, when we tested the effect of the combination of Src and MAPK inhibitors in females, primed with DAMGO, 7 days prior, we observed the PGE 2 -induced hyperalgesia at 30 minutes and 4 hours, (Fig. 6A) , also present after 10 days (Fig. 6B) , demonstrating no effect of the combination of Src and MAPK inhibitors in the expression (Fig. 6A) or maintenance (Fig. 6B) of type II priming in females. These findings indicate that the intracellular signaling pathway involved in the expression and maintenance of type II priming is sexually dimorphic.
Involvement of the G-protein-coupled estrogen receptor (GPR30) in the mechanism of type II priming in females
To evaluate if estrogen-dependent mechanisms mediate the resistance to the effect of the combination of Src and MAPK inhibitors in female rats, type II priming was induced by repeated DAMGO injections, and 24 hours later, intrathecal treatment with MM-ODN or AS-ODN for ER-a (Fig. 7A) , ER-b (Fig. 7B) , or GPR30 (Fig. 7C ) mRNA was initiated, for 5 consecutive days (once a day). On the sixth day, ;17 hours after the last injection of MM-or AS-ODN, the combination of the Src and MAPK inhibitors was injected followed, 10 minutes later, by injection of PGE 2 at the same site. While treatment with AS-ODN for ER-a did not impact the effect of the combination of Src and MAPK inhibitors on the expression of type II priming, as PGE 2 -induced hyperalgesia was still present at the fourth hour after injection (Fig. 7A) , in the rats treated with AS-ODN for ER-b the combination of Src and MAPK inhibitors attenuated the mechanical hyperalgesia induced by PGE 2 30 minutes after its injection (Fig. 7B, left panel) and inhibited the prolongation of PGE 2 -induced hyperalgesia at the fourth hour (Fig. 7B, left panel) . To determine whether the attenuation of type II priming by the combination of Src and MAPK inhibitors in these rats was permanent, PGE 2 was injected again, 7 days after the injection of inhibitors and 8 days after the last injection of ODNs (Fig. 7B, right panel) . At this point, PGE 2 -induced mechanical hyperalgesia was still present at the fourth hour, in all groups (Fig. 7B, right panel) , indicating that ER-b regulates the effect of Src and MAPK inhibitors only on the expression, but not in the maintenance, of DAMGO-induced type II priming in females. When PGE 2 was injected in primed females previously treated with AS-ODN for GPR30 that received the combination of Src and MAPK inhibitors, we observed 3 4) intradermal injections of DAMGO (1 mg) on the dorsum of the hind paw. Seven days later, vehicle (5 mL, black bars) or MAPK inhibitor U0126 (1 mg; gray bars) was injected at the same site, followed 10 minutes later by prostaglandin E 2 (PGE 2 ) (100 ng). In the group treated with U0126, PGE 2 -induced hyperalgesia was almost completely inhibited at the fourth hour (F 1,8 5 58.30; ***P , 0.0001, when the vehicle-and MAPK inhibitor-treated groups are compared; two-way repeated-measures analysis of variance (ANOVA) followed by Bonferroni post hoc test), indicating that MAPK plays a role in the expression of type II priming. (B) To determine whether the inhibition of type II priming by the MAPK inhibitor was permanent, PGE 2 (100 ng) was injected again at the same site, 10 days after the injection of U0126. At this time, PGE 2 -induced hyperalgesia was present at the fourth hour, indicating that MAPK does not play a role in the maintenance of type II priming (F 1,16 5 6.34; ns, when the vehicle and MAPK inhibitor groups are compared; two-way repeated-measures ANOVA followed by Bonferroni post hoc test). (C) Male rats received repeated (hourly 3 4) intradermal injections of DAMGO (1 mg) on the dorsum of the hind paw. Twelve days later, vehicle (5 mL, black bars) or FAK inhibitor (1 mg; white bars) was injected at the same site, followed 10 minutes later by PGE 2 (100 ng). In the group treated with the FAK inhibitor, PGE 2 -induced hyperalgesia was attenuated at 30 minutes and 4 hours (F 1,12 5 19.42; *P , 0.05 and ***P , 0.0001, when the vehicle-and FAK inhibitor-treated groups are compared; two-way repeated-measures ANOVA followed by Bonferroni post hoc test), indicating a small participation of FAK in the expression of DAMGO-induced type II priming (N 5 6 paws per group). attenuation of mechanical hyperalgesia induced by PGE 2 30 minutes after its injection (Fig. 7C, left panel) and the prolongation of PGE 2 -induced hyperalgesia at the fourth hour was completely blocked (Fig. 7C, left panel) , demonstrating that GPR30 also regulates the inhibitory effect of Src and MAPK in the expression of DAMGO-induced type II priming in female rats. However, when PGE 2 was injected again 7 ( Fig. 7C, middle panel) or 14 (Fig. 7C , right panel) days after the injection of a combination of Src and MAPK inhibitors, we observed that the PGE 2 -induced hyperalgesia was not present at the fourth hour (Fig. 7C , middle and right panel), indicating that GPR30 regulates the inhibitory effect of the combination of Src and MAPK inhibitors in DAMGOinduced type II priming in female rats.
Discussion
In the present experiments, we studied the maintenance mechanism of type II hyperalgesic priming 9 and compared it to that for the model of latent sensitization. 22, 49, 57 Given that naloxone induced mechanical hyperalgesia in DAMGO-primed paws, and itself induced hyperalgesic priming, the involvement of MOR was considered with respect to the expression and maintenance of type II priming. However, treatment with AS-ODN for MOR failed to inhibit the expression of DAMGO-induced type II priming (ie, prolongation of PGE 2 -induced hyperalgesia) and DAMGO-induced hyperalgesia, tested 8 days after the last injection of AS-ODN, confirming the presence of priming. Thus, we concluded that MOR is not necessary for either the expression or the maintenance of DAMGO-induced type II priming.
In our previous study of type II priming induced by repeated exposure to DAMGO, inhibitors of PKA (H-89), Src (SU 6656), and AS-ODN for phospholipase C-b3 mRNA 9,10 inhibited its expression, but did not reverse it in male rats. 9, 10 In this report, we evaluated the role of two other second messengers, MAPK and FAK, shown to be involved in PKA and Src signaling. 20, 35, 50, 53 Focal adhesion kinase is considered as an important scaffolding protein that interacts with several adaptors and signaling proteins at focal adhesions. 23, 61, 80 For example, the autophosphorylation of FAK creates a binding site for Src via the SH2 domain and activates it, not only enhancing FAK activity but also phosphorylating FAK-binding proteins to trigger a wide range of signaling pathways. 20 ### P , 0.0001, when days after CFA were compared to baseline (before CFA injection); one-way repeated measure analysis of variance (ANOVA) followed by Bonferroni post hoc test. F 1,60 5 114.97; ***P , 0.0001 or *P , 0.05, when ipsilateral [black circles] were compared to contralateral [white circles] paws; two-way repeated-measures ANOVA followed by Bonferroni post hoc test) and, progressively returning to baseline values, days 21 (ns) and 28 (ns). Change in the mechanical nociceptive threshold was not observed in the contralateral paws (A; white circles; F 5 1.253; P 5 0.3016; one-way repeated measure ANOVA followed by Bonferroni post hoc test). (B and C) Twenty-eight days after CFA injection, when the mechanical nociceptive threshold returned to baseline values in the ipsilateral paw, rats received an intrathecal injection of NTX (1 mg/20 mL), and the mechanical nociceptive threshold was evaluated 15, 30, 45, 60, 90, and 120 minutes after injection. A robust reduction in the mechanical nociceptive threshold was observed in both the contralateral [B; white circles; F 5 2.798; ***P , 0.0001, when time (minutes) after NTX was compared to baseline (before NTX); one-way repeated measure ANOVA followed by Bonferroni post hoc test] and in the ipsilateral [C; black circles; F 5 45.21; ***P , 0.0001, when time (min) after NTX was compared to baseline (before NTX); one-way repeated measure ANOVA followed by Bonferroni post hoc test] paws. One hundred twenty minutes after the injection of NTX, the mechanical nociceptive threshold returned to baseline, in both paws (ns; B, white circles; C, black circles) (N 5 6 rats). A different group of male rats that received CFA in 1 hind paw, 28 days before, was treated with an intrathecal injection of the combination of Src (SU 6656, 10 mg/5 mL) and MAPK (U0126; 10 mg/5 mL) inhibitors, 5 minutes before the intrathecal injection of NTX (1 mg/10 mL). At 15, 30, 45, 60, 90, and 120 minutes after the injection of NTX, we observed a complete inhibition of NTX-induced mechanical hyperalgesia in both paws, contralateral (B; F 1,50 5 84.72; ***P , 0.0001, when NTX group [white circles] was compared to Src and MAPK inhibitors followed by NTX group [black square]; two-way repeatedmeasures ANOVA followed by Bonferroni post hoc test; F 5 0.9309; P 5 0.4873, when time [minutes] after NTX was compared to baseline [before NTX]; one-way repeated measure ANOVA followed by Bonferroni post hoc test) and ipsilateral (C; F 1,50 5 149.49; ***P , 0.0001, when NTX group [black circles] was compared to Src and MAPK inhibitors followed by NTX group [white square]; two-way repeated-measures ANOVA followed by Bonferroni post hoc test; F 5 1.675; P 5 0.1616, when time [minutes] after NTX was compared to baseline [before NTX]; one-way repeated measure ANOVA followed by Bonferroni post hoc test). These findings support the suggestion that the CFA-induced latent sensitization is also dependent on Src and MAPK second messengers (N 5 6 rats). Similarly, FAK regulates cell adhesion disassembly and migration, by recruiting MAPK/ERK. 16, 78 In our experiments, both FAK inhibitor and the MAPK inhibitor U0126 inhibited the expression of type II priming, but not its maintenance. While these data confirm the participation of FAK and MAPK in the manifestation of the neuroplasticity, their activity alone cannot account for its maintenance. However, recent studies focused on cellsignaling pathways in non-neuronal cells have shown a requirement for simultaneous inhibition of Src and MAPK/ERK in the transition from dormant to latent state. 25, 26, 59 Of note, similar to our observations in the present study for type II priming, this latent state phenomenon in non-neuronal cells is also FAKdependent. 16, 78 Therefore, we evaluated the effect of a combination of Src and MAPK inhibitors in our model of DAMGO-induced type II priming. 9 We also tested this combination in the model of CFAinduced latent sensitization. 57 Of note, it has been suggested that the latent nociceptor sensitization observed in this model is produced by increased constitutive MOR activity, by augmented release of endogenous opioids in the spinal cord. 22, 57 Because this additional production of opioids could increase the activation of MOR at the central terminal of the nociceptor, it is possible that the latent sensitization observed is, actually, similar in mechanism to the one observed in our model of type II priming, also produced by increased activation of MOR. 9, 22, 42, 57 In fact, we found that the combination of the Src and MAPK inhibitor was able to permanently reverse both the prolongation of PGE 2 -induced hyperalgesia in DAMGOprimed paws and the NTX-induced decrease in mechanical nociceptive threshold in the model of latent sensitization. In addition, also in the models of CFA-induced latent sensitization and DAMGO-induced priming, a MOR inverse agonist produced hyperalgesia, suggesting that changes in the MOR could contribute to this plasticity. However, our finding that naloxone induces priming by itself and also produces hyperalgesia in DAMGO-primed paws, indicated that the latent sensitization mechanism may not involve tonic opioid-induced repression of nociceptive signaling, but rather a neuroplastic mechanism at the nociceptor, as demonstrated by the effect of the combination of Src and MAPK inhibitors, which also reversed naloxone-induced priming (data not shown). The central role of the Src/MAPK pathway in our model of opioidinduced neuroplasticity in the peripheral terminal of the primary afferent nociceptor and in the model of CFA-induced latent sensitization can be considered, thus a target for therapeutic interventions against painful conditions caused by chronic use of opioids.
Several studies have reported sexual dimorphism in mechanisms that play a role in the etiology of chronic pain, 15, 30, 40, 41 emphasizing the action of estrogen, in females. 15, 30, 41 Considering this possibility in our model of type II priming, we also evaluated the effect of the combination of Src and MAPK inhibitors on the maintenance of DAMGO-induced type II priming in female rats. Unexpectedly, the simultaneous inhibition of Src and MAPK did not reverse type II priming in females. Hence, we next evaluated if this lack of effect of the combination of Src and MAPK inhibitors on type II priming was due to a regulatory role of estrogen through the receptors ER-a, ER-b, and GPR30. We found that the treatment of female rats with AS-ODN for ER-b or GPR30, but not ER-a, restored the inhibitory effect of the combination of Src and MAPK inhibitors on the expression of DAMGO-induced type II priming. However, only in the GPR30 AS-ODN-treated group, the combination of inhibitors was able to permanently reverse priming. These data suggest the participation of estrogen, acting through GPR30, in the regulation of the second messengers that play a role in the maintenance of type II priming, induced by repeated exposure to MOR agonist DAMGO, in female rats. In good agreement with our findings, it has been demonstrated that 17b-estradiol induces cell proliferation, a process that is GPR30-and Src-mediated. 79 At the cellular level, GPR30 influences growth factor signaling pathways including trans-activation of signals such as epidermal growth factor receptor, intracellular Ca 21 mobilization, phosphoinositide-3-kinase translocation, Src activation, and MAP/ERK kinase activation and to modulate downstream transcription factor networks. 33, 34, 54, 55, 62, 66, 76, 77 Interestingly, the knockdown of GPR30 alone did not affect the maintenance of type II priming. One possible explanation is that the repeated activation of MOR might generate superactivation of Src and MAPK, which might be regulated by estrogen in females. Consequently, the knockdown of GPR30 allowed the simultaneous inhibition of Src and MAPK to reverse DAMGOinduced type II hyperalgesic priming, which is not necessary in males. Another possibility considers that the stimulation of GPR30 by estrogen is coupled to the activation of the same signaling molecules that participate in most membrane-initiated signaling cascades as opioid receptors, eg, protein kinase A, Figure 6 . Expression of type II priming does not depend on Src and mitogenactivated protein kinase (MAPK) in female rats. Female rats received repeated (hourly 3 4) intradermal injections of DAMGO (1 mg) on the dorsum of the hind paw. (A) Seven days later, vehicle (5 mL; black bars) or a combination of Src (SU 6656, 1 mg) and MAPK (U0126; 1 mg) inhibitors (gray bars) was intradermally injected on the dorsum of the hind paw, followed by injection of PGE 2 (100 ng), at the same site. Mechanical nociceptive threshold was evaluated 30 minutes and 4 hours after PGE 2 injection. Two-way repeated-measures analysis of variance (ANOVA) followed by Bonferroni post hoc test showed PGE 2 -induced hyperalgesia at 30 minutes, which was still present at the fourth hour after injection, in both groups, with no significant (ns) difference between the groups (F 1,20 5 2.10; P 5 0.1783, when vehicle and Src 1 MAPK inhibitors groups are compared; two-way repeated-measures ANOVA followed by Bonferroni post hoc test). (B) Ten days after the injection with Src and MAPK inhibitors, PGE 2 (100 ng; intradermally) was again injected. PGE 2 -induced hyperalgesia was present 30 minutes and 4 hours later, in both groups (ns, when the vehicle-and Src 1 MAPK inhibitors-treated groups are compared; two-way repeatedmeasures ANOVA followed by Bonferroni post hoc test), indicating that Src and MAPK do not play a role in the expression or maintenance of priming in female rats, possibly due to sexual dimorphic role of Src and MAPK in this type of neuroplasticity (N 5 6 paws per group). On the sixth day, ;17 hours after the last injection of MM-ODN or AS-ODN, rats received intradermal injection of the combination of Src (SU 6656; 1 mg) and MAPK (U0126, 1 mg) inhibitors (black and gray bars) on the dorsum of the hind paw, followed, 10 minutes later, by prostaglandin E 2 (PGE 2 ) (100 ng) at the same site. The mechanical nociceptive threshold was evaluated 30 minutes and 4 hours after PGE 2 injection. (A) PGE 2 -induced hyperalgesia was present 30 minutes and 4 hours later, in all groups (F 1,33 5 1.36; P 5 0.2523, when the groups are compared; two-way repeated-measures analysis of variance (ANOVA) followed by Bonferroni post hoc test), indicating that the knockdown of ER-a did not affect the inability of the combination of Src and MAPK inhibitors to reverse priming in female rats. (B, left panel) PGE 2 -induced hyperalgesia at 30 minutes was partially attenuated in the AS-ODN for ER-b-treated group, that received the combination of Src and MAPK inhibitors (gray bar; **P , 0.01, when the MM-ODN (black bar) and AS-ODN (white bar) groups are compared). At the fourth hour, the prolongation of PGE 2 -induced hyperalgesia was still attenuated in the AS-ODN for ER-b-treated group that received Src and MAPK inhibitors (gray bar; F 2,33 5 38.54; ***P , 0.001; two-way repeated-measures ANOVA followed by Bonferroni post hoc test); Right panel. To determine whether the reversal of DAMGO-induced priming by treatment with AS-ODN for ER-b in rats that received the combination of Src and MAPK inhibitors, was permanent, PGE 2 (100 ng) was injected again at the same site 8 days after the last ODN injection. We observed that PGE 2 -induced mechanical hyperalgesia was still present at the fourth hour, indicating the presence of type II priming (F 2,66 5 2.64; P 5 0.0862, when the groups are compared; two-way repeated-measures ANOVA followed by Bonferroni post hoc test). (C, left panel) PGE 2 -induced hyperalgesia was inhibited at 30 minutes and 4 hours in the group that had previously been treated with AS-ODN for GPR30 and received the combination of Src and MAPK inhibitors (gray bars; F 2,33 5 62.37; **P , 0.001 and ***P , 0.0001, when AS-ODN, Src and MAPK inhibitors is compared to AS-ODN or MM-ODN, Src and MAPK inhibitors; two-way repeated-measures ANOVA followed by Bonferroni post hoc test); Middle panel. To determine whether the reversal of DAMGO-induced priming by the treatment with AS-ODN for GPR30 that received the combination of Src and MAPK inhibitors was permanent, PGE 2 was injected again at the same site 8 days after the last ODN injection. Prostaglandin E 2 -induced mechanical hyperalgesia was attenuated at the fourth hour in the group previously treated with AS-ODN for GPR30 that received the combination of Src and MAPK inhibitors (gray bar; F 2,66 5 31.76; ***P , 0.0001, when AS-ODN, Src and MAPK inhibitors is compared to AS-ODN or MM-ODN, Src and MAPK inhibitors; two-way repeated-measures ANOVA followed by Bonferroni post hoc test); Right panel. Additionally, when PGE 2 (100 ng; intradermally) was injected again, 15 days after the last injection of ODNs and 14 days after the injection of the combination of Src and MAPK inhibitors, PGE 2 -induced mechanical hyperalgesia was attenuated at the fourth hour in the group previously treated with AS-ODN for GPR30 that received the combination of Src and MAPK inhibitors (gray bar; F 2,66 5 85.64; ***P , 0.0001, when AS-ODN, Src and MAPK inhibitors is compared to the AS-ODN or MM-ODN, Src and MAPK inhibitors; two-way repeated-measures ANOVA followed by Bonferroni post hoc test) indicating that GPR30 regulates the inhibitory effect of the combination of Src and MAPK inhibitors on DAMGO-induced type II priming, in female rats. Of note, the mechanical nociceptive thresholds before the treatment with MM-or AS-ODN were not different when compared to the mechanical nociceptive thresholds ;17 hours after the last injection of ODNs. In addition, the treatment with AS-ODN alone (white bars) was not able to inhibit the expression and/or maintenance of DAMGO-induced type II priming (N 5 12 paws per group). www.painjournalonline.comprotein kinase B, protein kinase C, phospholipase C, inositol triphosphate, MAPK, ERK, tyrosine kinases, etc. 45 Because of the overlapping of the secondary messenger pathways, activation of GPR30 by estrogen is postulated to influence the signaling cascades of the opioid receptors, leading to the sex differences in the effects of opioids because of different GPR30 expression patterns between males and females. 45 However, the nature of the interaction of Src and MAPK/ERK mediating the state switch, in any cell type, as well as sex differences, remains to be elucidated.
In conclusion, the maintenance of type II hyperalgesic priming induced by repeated exposure to an inhibitory G-protein-coupled receptor agonist DAMGO and the latent sensitization, are dependent on mechanisms mediated by an interaction between 2 second messengers, Src and MAPK, 52, 74 which in female rats is regulated by GPR30 signaling (Fig. 8) . Understanding the Figure 8 . Schematic representation of the mechanisms involved in the maintenance of DAMGO-induced type II hyperalgesic priming in the male and female rat. In (A) the induction of type II priming by repeated (hourly 3 4) stimulation of MOR in IB4-negative nociceptors is illustrated. The repeated administration of DAMGO (a MOR agonist) stimulates a yet-to-be-determined pathway that produces neuroplastic changes in the nociceptor expressed as prolongation of PGE 2 -induced hyperalgesia. 9 The maintenance of DAMGO-induced type II hyperalgesic priming is markedly dependent on both Src and MAPK/ERK in male (B), which is regulated through GPR30 in female (C) rats. EP, prostaglandin E 2 receptor; GPCR, G-protein-coupled estrogen receptor 30; MOR, mu-opioid receptor; Ga i , inhibitory G-protein a subunit; IB4, isolectin B4; MAPK/ERK, mitogen-activated protein kinase/extracellular signal-related kinase; PGE 2 , prostaglandin E 2 ; Src, Src tyrosine kinase. 
